Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.75 |
| ▸ | L3MBTL3 | Q96JM7 | 5/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.38 |
| ▸ | KHK | P50053 | 4/20 | 0.33 |
| ▸ | MBTD1 | Q05BQ5 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | ARG1 | P05089 | 1/20 | 0.31 |
| ▸ | ARG2 | P78540 | 1/20 | 0.31 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.31 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1447785 | 1.00 | HTR6 (0.75) | HTR6L3MBTL3L3MBTL1KHKMBTD1 | |
| SCHEMBL223255 | 1.00 | HTR6 (0.75) | HTR6L3MBTL3L3MBTL1KHKMBTD1 | |
| Hydrochloric Acid SCHEMBL3335525 | 0.98 | HTR6 (0.72) | HTR6L3MBTL3L3MBTL1KHKMBTD1 | |
| SCHEMBL714244 | 0.98 | HTR6 (0.72) | HTR6L3MBTL3L3MBTL1KHKMBTD1 | |
| Hydrochloric Acid SCHEMBL1736189 | 0.98 | HTR6 (0.72) | HTR6L3MBTL3L3MBTL1KHKMBTD1 | |
| Hydrochloric Acid SCHEMBL1809050 | 0.98 | HTR6 (0.72) | HTR6L3MBTL3L3MBTL1KHKMBTD1 | |
| SCHEMBL1094767 | 0.98 | HTR6 (0.72) | HTR6L3MBTL3L3MBTL1KHKMBTD1 | |
| Hydrochloric Acid SCHEMBL17311103 | 0.98 | HTR6 (0.72) | HTR6L3MBTL3L3MBTL1KHKMBTD1 | |
| SCHEMBL10265670 | 0.98 | HTR6 (0.72) | HTR6L3MBTL3L3MBTL1KHKMBTD1 | |
| Hydrochloric Acid SCHEMBL1814485 | 0.98 | HTR6 (0.72) | HTR6L3MBTL3L3MBTL1KHKMBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| US-20250304577-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2025-10-02 | — | — | US | disclosed |
| US-20240368193-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-11-07 | — | — | US | disclosed |
| US-11806346-B2 | HTT modulators for treating Huntington's disease | CHDI FOUNDATION, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| CN-116437913-A | Pharmaceutical compounds for treating complement-mediated disorders | 艾其林医药公司 | 2023-07-14 | — | — | CN | disclosed |
| US-20220409615-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | CHDI FOUNDATION, INC. | 2022-12-29 | — | — | US | disclosed |
| EP-3995495-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2022-05-11 | — | — | EP | disclosed |
| US-20200150023-A1 | Instrument and Method for Optical Particle Sensing | INVITROX INC (US) | 2020-05-14 | — | — | US | disclosed |
| EP-3626717-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2020-03-25 | — | — | EP | disclosed |
| US-10370405-B2 | C-3 novel triterpenone with C-28 amide derivatives as HIV inhibitors | HETERO LABS LIMITED (IN) | 2019-08-06 | — | — | US | disclosed |
| WO-2007121923-A1 | PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| EP-1841768-A1 | PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2007-10-10 | — | — | EP | disclosed |
| WO-2007093364-A1 | AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (DE) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007093363-A1 | NOVEL AZACYCLY-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (DE) | 2007-08-23 | — | — | WO | disclosed |
| WO-2006134481-A1 | INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1 | PFIZER INC. (US) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006097260-A1 | ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY | NOVARTIS AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006074925-A1 | PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
| US-7060836-B2 | Lactams as tachykinin antagonists | PFIZER, INC (US) | 2006-06-13 | — | — | US | disclosed |
| EP-1456200-A1 | LACTAMS AS TACHYKININ ANTAGONISTS | Pfizer Limited (GB) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003051868-A1 | LACTAMS AS TACHYKININ ANTAGONISTS | PFIZER LIMITED (GB) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220409615-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, ATXN2 | HTR6 8/4885L3MBTL3 2351/4885L3MBTL1 1254/4885 |
| US-20250304577-A1 | TYK2 INHIBITORS | TYK2, JAK2, JAK1 | HTR6 2272/4885L3MBTL3 3014/4885L3MBTL1 2886/4885 |
| US-11806346-B2 | HTT modulators for treating Huntington's disease | HTT, HYPK, ATXN2 | HTR6 8/4885L3MBTL3 2351/4885L3MBTL1 1254/4885 |
| US-20240368193-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | HTR6 4845/4885L3MBTL3 2353/4885L3MBTL1 1876/4885 |
| US-10370405-B2 | C-3 novel triterpenone with C-28 amide derivatives as HIV inhibitors | ERG28, CCR3, GTF3C3 | HTR6 4454/4885L3MBTL3 1400/4885L3MBTL1 2147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.